EndoGastric Solutions Reports Two-Year Durability Data from TIF Registry for GERD Patients Choosing Transoral Incisionless Fundoplication (TIF®)
SAN MATEO, Calif. (Oct. 29, 2014)–EndoGastric Solutions® (EGS) announced publication of US registry data showing that long-term gastroesophageal reflux disease (GERD) sufferers who underwent an incisionless procedure maintained symptom relief without the need to take proton pump inhibitor medicines for two years.
Data from the EndoGastric Solutions® (EGS) Transoral Incisionless Fundoplication (TIF®) registry show that outcomes from the procedure observed at six and 12 months remained stable across a range of evaluation methodologies at 24-month follow-up. The TIF procedure reconstructs the gastroesophageal valve which has been found to be the primary cause of GERD.
“These new findings demonstrate the long-term positive outcomes that come from treating the underlying cause of GERD with this innovative, incisionless approach,” said Reginald Bell, MD, general surgeon at SurgOne Foregut Institute in Englewood, CO and lead author of the paper. “Because the side-effect profile of this procedure is almost non-existent and patients were able to remain off medical therapy, patients now have a very attractive option that fills the treatment gap between PPIs and traditional surgery.”
Patient quality of life scores, measured using a series of validated questionnaires, improved and were sustained compared to baseline at 6-, 12-, and 24-month follow-up intervals (p=<0.001). The data show that quality-of-life scores remained the same over time, suggesting durability of outcomes from 6 months post procedure to 24-month follow-up. Abstract is available here.
“EGS remains dedicated to developing safe, effective, and low-risk technologies and procedures that treat the tens of thousands of GERD patients who fall into the treatment gap between medical prescription therapy and invasive surgery,” said Skip Baldino, EGS President and CEO. “We are extremely pleased to see the patients who utilized the TIF procedure feeling so much better for so long without the need for medicines to control their symptoms. Given these long-term, real-life outcomes, we believe our TIF procedure can significantly enhance the quality of life for GERD patients.”
The results were published in the November issue of the journal American Surgeon in a study designed to assess the impact of the TIF procedure on patients with chronic GERD at 6-, 12- 24- and 36 month follow-up points. The publication reports results following TIF procedures in 127 consecutive patients prospectively enrolled in the registry and treated at 14 U.S. centers, including 13 general surgery practices and one gastroenterology practice.
NP02418-01B
About GERD
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease that affects nearly 20 percent of the U.S. population. It is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. In the United States (U.S.), GERD is the most common gastrointestinal-related diagnosis physicians make during clinical visits. Some patients may have mild or moderate symptoms of GERD, while others have more severe manifestations causing chronic heartburn, asthma, chronic cough, and hoarse voice or chest pain. Left untreated, GERD can develop into a pre-cancerous condition called Barrett’s esophagus, which is a precursor for esophageal cancer. The first treatment recommendation for patients with GERD is to make lifestyle changes (e.g., diet, scheduled eating times and sleeping positions). Proton pump inhibitor (PPI) medications are commonly used to treat GERD, but there are a variety of health complications associated with long-term dependency on PPIs, and more than 10 million Americans are refractory to PPI therapy and may opt for surgery.
About Transoral Incisionless Fundoplication (TIF® 2.0 procedure) for Reflux
The TIF 2.0 procedure enables an incisionless approach to fundoplication in which a device is inserted through the mouth, down the esophagus and into the upper portion of the stomach. This approach offers patients looking for an alternative to traditional surgery an effective treatment option to correct the underlying cause of GERD. Based on clinical studies, most patients stopped using daily medications to control their symptoms and had their esophageal inflammation (esophagitis) eliminated up to five years after the TIF 2.0 procedure. Additionally, clinical results have demonstrated that concomitant laparoscopic hiatal hernia repair (LHHR) immediately followed by TIF 2.0 procedure is safe and effective in patients requiring repair of both anatomical defects.
Over 22,000 TIF procedures have been performed worldwide. More than 100 peer-reviewed papers have consistently documented the sustained improved clinical outcomes and exemplary safety profile the TIF procedure provides to patients suffering from GERD. For more information, please visit www.GERDHelp.com.
About Reimbursement
With the support of clinical societies, commercial and federal insurance providers, representing more than 100 million lives, have recognized the value of the TIF 2.0 procedure through recently expanded coverage policies. The TIF 2.0 procedure is a covered benefit for all Medicare beneficiaries across the country.
For the TIF 2.0 procedure, physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty. CPT is a registered trademark of the American Medical Association.
About EsophyX® Technology
The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids from refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope, and enables creation of a 3 cm, 270° esophagogastric fundoplication. The U.S. Food and Drug Administration cleared the original EsophyX device in 2007. The evolving technology, including the latest iteration EsophyX Z+, launched in 2017, enables surgeons and gastroenterologists to use a wide selection of endoscopes to treat the underlying anatomical cause of GERD.
Indications
The EsophyX device, with SerosaFuse® fasteners and accessories, is indicated for use in transoral tissue approximation, full thickness plication and ligation in the gastrointestinal tract. It is indicated for the treatment of symptomatic chronic GERD in patients who require and respond to pharmacological therapy. The device is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia ≤ 2 cm in size in patients with symptomatic chronic GERD. Patients with hiatal hernias larger than 2 cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2 cm or less.
About EndoGastric Solutions®
Based in Redmond, Washington, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop products and procedures to treat gastrointestinal diseases, including the TIF 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. Join the conversation on Twitter: @GERDHelp Facebook: GERDHelp and LinkedIn: EndoGastric Solutions.
# # #
Contact:
Debbie Donovan
EndoGastric Solutions, Inc.
Phone: +1 408-621-0216
ddonovan@endogastricsolutions.com
Erich Sandoval
Lazar Partners
Phone: +1 917-497-2867
esandoval@lazarpartners.com